Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: A prospective cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 1, 2014, Pages 22-29

  O'Donnell, Max R ^a,b,c   Wolf, Allison ^a   Werner, Lise ^c   Horsburgh, C Robert ^d   Padayatchi, Nesri ^c,e  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b Mailman School of Public Health   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

adherence; attitudes and beliefs; extensively drug resistant tuberculosis; HIV AIDS; knowledge

Indexed keywords

ANTIRETROVIRUS AGENT; CAPREOMYCIN; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TERIZIDONE; TUBERCULOSTATIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH BELIEF; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SHORT COURSE THERAPY; SOUTH AFRICA; TREATMENT OUTCOME; ADOLESCENT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; QUESTIONNAIRE; SOCIOECONOMICS; STATISTICAL MODEL; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COHORT STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84906083679     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000221     Document Type: Article

References (41)

1. WHO. Global Tuberculosis Report 2013. WHO/HTM/TB/2013.15. Geneva, Switzerland: World Health Organization, 2013.
2. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi-And extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33: 1085-1094.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580.
4. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-1807.
5. O'Donnell MR, Padayatchi N, Master I, et al. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009;13:855-861.
6. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537-2545.
7. WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva: WHO; 2010.
8. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-Analysis of 9, 153 patients. PLoS Med. 2012;9: e1001300.
9. Abdool-Karim Q, Abdool-Karim SS. The evolving HIV epidemic in South Africa. Int J Epidemiol. 2002;31:37-40.
10. O'Donnell MR, Padayatchi N, Kvasnovsky C, et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013;19:413-424.
11. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug-And extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80-86.
12. Shean K, Streicher E, Pieterson E, et al. Drug-Associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8:e63057.
13. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383:1230-1239.
14. O'Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis. 2013;208:40-49.
15. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22:75-82.
16. Kulkarni P, Akarte S, Mankeshwar R, et al. Non-Adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment. Ann Med Health Sci Res. 2013;3:67-74.
17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
18. Stephenson J. AIDS researchers target poor adherence. JAMA. 1999; 281:1069.
19. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
20. Glass TR, Rotger M, Telenti A, et al. Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS One. 2012;7:e29186.
21. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet. 2004;363:814-819.
22. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis. 2008;88(suppl 1): S85-S92.
23. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336:484-487.
24. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4:e238.
25. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-Analysis. AIDS Behavior. 2011; 15:1381-1396.
26. Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDS Behavior. 2013; 17:284-297.
27. Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of anti-retroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behavior. 2006;10:227-245.
28. Potchoo Y, Tchamdja K, Balogou A, et al. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association "Espoir Vie Togo" in Togo, West Africa. BMC Clin Pharmacol. 2010;10:11.
29. Xu W, Lu W, Zhou Y, et al. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:169.
30. Naidoo P, Peltzer K, Louw J, et al. Predictors of tuberculosis (TB) and antiretroviral (ARV) medication non-Adherence in public primary care patients in South Africa: a cross sectional study. BMC Public Health. 2013;13:396.
31. Finlay A, Lancaster J, Holtz TH, et al. Patient-And provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study. BMC Public Health. 2012;12:56.
32. Rowe KA, Makhubele B, Hargreaves JR, et al. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9:263-269.
33. Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10:651.
34. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
35. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12: 255-266.
36. Balikuddembe R, Kayiwa J, Musoke D, et al. Plasma drug level validates self-reported adherence but predicts limited specificity for nonadherence to antiretroviral therapy. ISRN Pharmacol. 2012;2012:274978.
37. Brust JC, Lygizos M, Chaiyachati K, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One. 2011;6:e15841.
38. Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-Adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23:601-611.
39. Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010; 14:454-463.
40. Mindachew M, Deribew A, Tessema F, et al. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health. 2011;11:916.
41. Klopper M, Warren RM, Hayes C, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2013;19:449-455.